NCT05773274 RECRUITING Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
NCT05724108 ACTIVE NOT RECRUITING Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT04665739 RECRUITING Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT02834013 ACTIVE NOT RECRUITING Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
NCT07129252 RECRUITING A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Crinetics Pharmaceuticals Inc.
NCT04888481 RECRUITING 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
University of Alberta
NCT04848337 ACTIVE NOT RECRUITING Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
University of Michigan Rogel Cancer Center
NCT04924075 RECRUITING Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Merck Sharp & Dohme LLC
NCT01174121 RECRUITING Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT03412877 RECRUITING Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
NCT01841736 ACTIVE NOT RECRUITING Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
NCT05636618 RECRUITING Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
NCT05988918 ACTIVE NOT RECRUITING Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
NCT03206060 RECRUITING Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Cancer Institute (NCI)
NCT05969860 RECRUITING At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT02174549 RECRUITING Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison Ltd.
NCT04074135 RECRUITING Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT03110978 ACTIVE NOT RECRUITING Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT06638931 RECRUITING Agnostic Therapy in Rare Solid Tumors
Instituto do Cancer do Estado de São Paulo
NCT05153772 ACTIVE NOT RECRUITING Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
Orano Med LLC
NCT06607692 RECRUITING Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Fundación de investigación HM
NCT04291885 ACTIVE NOT RECRUITING Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Melanoma and Skin Cancer Trials Limited
NCT05048901 RECRUITING Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
NCT04086485 RECRUITING Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Cancer Institute (NCI)
NCT06228066 RECRUITING Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Cancer Institute (NCI)
NCT03950609 ACTIVE NOT RECRUITING Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
NCT05500391 RECRUITING Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Centre Oscar Lambret
NCT05746208 RECRUITING Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
NCT03074513 ACTIVE NOT RECRUITING Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
NCT06427798 RECRUITING Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
National Cancer Institute (NCI)
NCT02568267 ACTIVE NOT RECRUITING Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT04969887 ACTIVE NOT RECRUITING Combination Immunotherapy in Rare Cancers Under InvesTigation
Olivia Newton-John Cancer Research Institute
NCT04711135 ACTIVE NOT RECRUITING Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Advanced Accelerator Applications
NCT07404176 RECRUITING Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors
Tata Memorial Hospital
NCT07151391 RECRUITING The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
NCT04954820 RECRUITING Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
Institut du Cancer de Montpellier - Val d'Aurelle
NCT06055439 RECRUITING A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Therapeutics
NCT07357623 RECRUITING Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Shanghai Chest Hospital
NCT06232564 ACTIVE NOT RECRUITING A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs
Imperial College London
NCT03891784 ACTIVE NOT RECRUITING Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
NCT03600233 ACTIVE NOT RECRUITING Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
NCT03728361 ACTIVE NOT RECRUITING Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Dwight Owen
NCT05040360 RECRUITING Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
SWOG Cancer Research Network
NCT06943521 RECRUITING A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
NCT04339036 RECRUITING CapTemY90 for Grade 2/3 NET Liver Metastases
Abramson Cancer Center at Penn Medicine
NCT05263050 RECRUITING Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
NCT05255159 ACTIVE NOT RECRUITING Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
University of Alberta
NCT06790706 RECRUITING IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Hospices Civils de Lyon
NCT07121478 ENROLLING BY INVITATION Patients With High-grade Pancreatic Neuroendocrine Tumors
National Cancer Center, Korea
NCT02628067 ACTIVE NOT RECRUITING Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Merck Sharp & Dohme LLC
NCT05385861 ENROLLING BY INVITATION Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
National Health Research Institutes, Taiwan
NCT06345079 RECRUITING Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Australasian Gastro-Intestinal Trials Group
NCT04837885 RECRUITING Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
University Hospital, Bordeaux
NCT06395402 RECRUITING 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
University of Iowa
NCT03935893 RECRUITING Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT06455358 RECRUITING 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
University Hospital, Basel, Switzerland
NCT03145857 RECRUITING A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
AHS Cancer Control Alberta
NCT06056362 RECRUITING Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Peking Union Medical College Hospital
NCT05247905 ACTIVE NOT RECRUITING Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Alliance for Clinical Trials in Oncology
NCT06764368 NOT YET RECRUITING Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
Beijing Chest Hospital
NCT02185443 RECRUITING Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
University of Sao Paulo
NCT02749331 ACTIVE NOT RECRUITING Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
Uppsala University
NCT05554003 RECRUITING Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
European Institute of Oncology
NCT05199272 ACTIVE NOT RECRUITING A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
NCT06038461 RECRUITING An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04166006 RECRUITING A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT03454763 ACTIVE NOT RECRUITING Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT05176665 RECRUITING EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Shanghai EpimAb Biotherapeutics Co., Ltd.
NCT02754297 ACTIVE NOT RECRUITING Personalized PRRT of Neuroendocrine Tumors
CHU de Quebec-Universite Laval
NCT04524208 ACTIVE NOT RECRUITING A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
Karsten Gavenis
NCT06045260 RECRUITING "Receptor Radionuclide Therapy With 177Lu-DOTATOC
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT06540937 RECRUITING Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05997056 RECRUITING Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Aadi Bioscience, Inc.
NCT06472388 RECRUITING Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
AC Camargo Cancer Center
NCT04893785 RECRUITING A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
National Cancer Institute, Naples
NCT05396118 ENROLLING BY INVITATION Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
NCT04889742 NOT YET RECRUITING Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
Charite University, Berlin, Germany
NCT06158516 NOT YET RECRUITING A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Changhai Hospital
NCT05894486 NOT YET RECRUITING Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
Peking University
NCT05361668 COMPLETED Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
NCT03211988 TERMINATED Entinostat Neuroendocrine (NE) Tumor
Antonio Fojo
NCT05000294 SUSPENDED Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
NCT04505553 COMPLETED Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
NCT05987176 TERMINATED Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
Imperial College London
NCT04362436 COMPLETED TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets
Imperial College London
NCT03290079 COMPLETED Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03910660 COMPLETED A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
NCT05077384 COMPLETED Open-label Study of Surufatinib in Japanese Patients
Hutchmed
NCT04579679 TERMINATED Open-Label Surufatinib in European Patients With NET
Hutchmed
NCT02678780 COMPLETED Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
Grupo Espanol de Tumores Neuroendocrinos
NCT02611024 COMPLETED Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
NCT04400474 COMPLETED Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Grupo Espanol de Tumores Neuroendocrinos
NCT03037385 COMPLETED Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Hoffmann-La Roche
NCT04579757 TERMINATED Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
NCT05251233 TERMINATED Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Washington University School of Medicine
NCT06456723 COMPLETED Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.
Imperial College London
NCT02348749 COMPLETED 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
Memorial Sloan Kettering Cancer Center
NCT02489903 COMPLETED RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
NCT04438304 COMPLETED A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Clarity Pharmaceuticals Ltd
NCT02691078 COMPLETED Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Latin American Cooperative Oncology Group
NCT04197310 COMPLETED Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
NCT03980925 COMPLETED Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
NCT02489604 TERMINATED Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02736500 COMPLETED Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02736448 TERMINATED 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT03095274 COMPLETED Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Grupo Espanol de Tumores Neuroendocrinos
NCT02724540 COMPLETED Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
Abramson Cancer Center at Penn Medicine
NCT03278379 COMPLETED Avelumab in G2-3 NET
Sunnybrook Health Sciences Centre
NCT03034200 COMPLETED Phase 2 Study of ONC201 in Neuroendocrine Tumors
Peter Anderson
NCT05568017 TERMINATED Neoadjuvant PRRT With Y-90-DOTATOC in pNET
European Institute of Oncology
NCT05610826 WITHDRAWN Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
University of Chicago
NCT03070301 COMPLETED A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
NCT01678664 COMPLETED Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Federation Francophone de Cancerologie Digestive
NCT04931420 WITHDRAWN Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
University of Chicago
NCT03870399 COMPLETED Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
AC Camargo Cancer Center
NCT04614766 WITHDRAWN A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
David Bushnell
NCT01466036 COMPLETED Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
NCT03420521 TERMINATED Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02399215 COMPLETED Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
NCT06155994 COMPLETED 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours
Medical University Innsbruck
NCT02859064 TERMINATED Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
NCT02893930 COMPLETED Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01782443 COMPLETED Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
NCT04644315 TERMINATED A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Hoffmann-La Roche
NCT02592707 TERMINATED Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Ipsen
NCT00427349 COMPLETED AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
NCT03043664 COMPLETED Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Duke University
NCT04385992 COMPLETED Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET
IRCCS San Raffaele
NCT04543955 TERMINATED Telotristat With Lutathera in Neuroendocrine Tumors
Lowell Anthony, MD
NCT01237457 COMPLETED 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Ebrahim S Delpassand
NCT04276597 WITHDRAWN Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Excel Diagnostics and Nuclear Oncology Center
NCT01253161 COMPLETED Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
NCT04915144 WITHDRAWN 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
NCT04713202 WITHDRAWN Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
Chandrikha Chandrasekhara
NCT03273712 COMPLETED Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
NCT01177397 COMPLETED Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
NCT03079440 COMPLETED TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
NCT03722511 COMPLETED Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
Lowell Anthony, MD
NCT01229943 COMPLETED Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03278275 COMPLETED PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
Rigshospitalet, Denmark
NCT03271281 COMPLETED PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
Rigshospitalet, Denmark
NCT03365791 COMPLETED PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis Pharmaceuticals
NCT04831567 WITHDRAWN Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors
AC Camargo Cancer Center
NCT04318561 COMPLETED Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors
Peking Union Medical College Hospital
NCT04672876 WITHDRAWN Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
University of Chicago
NCT02259725 COMPLETED Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
NCT02936323 COMPLETED PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Tarveda Therapeutics
NCT01869725 COMPLETED Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
Sue O'Dorisio
NCT02838342 COMPLETED Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
Centre Hospitalier Universitaire de Besancon
NCT01619865 COMPLETED Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
Sue O'Dorisio
NCT03190213 TERMINATED Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
University of Utah
NCT03670030 TERMINATED A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Robert Ramirez
NCT03923257 WITHDRAWN Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
Sue O'Dorisio
NCT02955069 COMPLETED Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Novartis Pharmaceuticals
NCT02939651 COMPLETED A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Fox Chase Cancer Center
NCT03220217 COMPLETED To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Ipsen
NCT02441062 COMPLETED Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Sue O'Dorisio
NCT03042780 TERMINATED FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
NCT02420691 COMPLETED Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
M.D. Anderson Cancer Center
NCT02113800 COMPLETED Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
AIO-Studien-gGmbH
NCT00843531 TERMINATED RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
NCT02575300 COMPLETED Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT04129255 COMPLETED Octreotide LAR in the Induction of Immunologic Response in NENs Patients
National Cancer Institute, Naples
NCT02315625 TERMINATED Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Cancer Institute (NCI)
NCT02402062 COMPLETED A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
NCT00576680 COMPLETED RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
NCT02067988 COMPLETED Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study
UMC Utrecht
NCT04296149 COMPLETED Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe
European Institute of Oncology
NCT00985946 TERMINATED Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
NCT01967537 COMPLETED Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT02177773 TERMINATED GA-68 DOTA-TOC of Somatostatin Positive Malignancies
University of California, San Francisco
NCT02162446 COMPLETED 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Ipsen
NCT01456078 COMPLETED A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
Lund University Hospital
NCT00781911 COMPLETED A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
NCT01648465 TERMINATED Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Hellenic Cooperative Oncology Group
NCT01280201 COMPLETED Pazopanib as Single Agent in Advanced NETs
Grupo Espanol de Tumores Neuroendocrinos
NCT02231762 COMPLETED Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Ipsen
NCT01290536 COMPLETED Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Nicholas Fidelman, MD
NCT00605566 COMPLETED Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
University Health Network, Toronto
NCT00688623 COMPLETED RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Novartis Pharmaceuticals
NCT01010126 COMPLETED Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
NCT01994213 TERMINATED A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT01262235 COMPLETED A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Arbutus Biopharma Corporation
NCT01435122 COMPLETED A Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT02279602 COMPLETED Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Mateon Therapeutics
NCT01024387 COMPLETED AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
NCT02299089 COMPLETED Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Camurus AB
NCT02132468 COMPLETED A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
Mateon Therapeutics
NCT00903396 TERMINATED Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
NCT01719861 TERMINATED Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Joel Neal
NCT01845675 COMPLETED Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Peking Union Medical College Hospital
NCT00947167 TERMINATED A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Pamela L. Kunz
NCT00965250 COMPLETED Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
National Cancer Institute (NCI)
NCT02078843 TERMINATED Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Insel Gruppe AG, University Hospital Bern
NCT01048086 WITHDRAWN 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
NCT01658436 COMPLETED BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Novartis Pharmaceuticals
NCT01628913 TERMINATED Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis Pharmaceuticals
NCT01099540 COMPLETED Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Samsung Medical Center
NCT00696930 WITHDRAWN Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Molecular Insight Pharmaceuticals, Inc.
NCT00610129 COMPLETED Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Memorial Sloan Kettering Cancer Center
NCT01215578 TERMINATED Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Assistance Publique - Hôpitaux de Paris
NCT01121562 COMPLETED Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
NCT00780663 COMPLETED Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Cylene Pharmaceuticals
